Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;148(4):975-984.
doi: 10.1007/s00432-021-03693-5. Epub 2021 Jun 18.

Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study

V Leclerc  1   2 , L Karlin  3 , C Herledan  1   2 , L Marchal  1 , A Baudouin  1 , A Gouraud  4 , A G Caffin  1 , V Larbre  1   2 , A Lazareth  3 , E Bachy  3 , G Salles  3 , H Ghesquières  3 , C Rioufol #  1   2 , F Ranchon #  5   6
Affiliations

Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study

V Leclerc et al. J Cancer Res Clin Oncol. 2022 Apr.

Abstract

Purpose: The aim of this study is to assess international guidelines implementation concerning thromboprophylaxis strategy in myeloma patients treated with immunomodulatory drugs.

Methods: This retrospective study includes multiple myeloma patients treated with immunomodulatory drugs between 2014 and 2017 in the Hematology department of a teaching hospital (Hospices Civils de Lyon, France) and followed by the multidisciplinary care plan for cancer outpatients ONCORAL (ONCological care for outpatients with ORAL anticancer drugs). Data from immunomodulatory drugs administration, thromboprophylaxis strategy and thrombotic events were collected from medical files. Adherence to 2010 International Myeloma Working Group (IMWG) guidelines was assessed.

Results: 213 patients received at least one immunomodulatory drug: lenalidomide (60.9%), pomalidomide (24.0%) and thalidomide (15.1%). About two third of treatment lines (66.2%) were in accordance with IMWG recommendations. Among the others, 30.5% and 69.5% had thromboprophylaxis, respectively, superior or inferior to IMWG recommendations. 37 venous thrombotic events and 4 arterial thromboembolisms (one patient experienced both a stroke and deep venous thrombosis simultaneously) were reported.

Conclusion: Thromboprophylaxis was systematically performed in myeloma patients treated with immunomodulatory drugs in this real-life retrospective cohort. However, the choice of anticoagulant or anti-platelet agent remains debatable, as adherence to existing guidelines was variable.

Keywords: Anticoagulants; Immunomodulatory drugs; Multiple myeloma; Thromboprophylaxis; Thrombosis.

PubMed Disclaimer

Conflict of interest statement

No conflict of interest to declare.

References

    1. Alexander M, Teoh KC, Lingaratnam S, Kirsa S, Mellor JD (2013) Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital: Thromboprophylaxis in multiple myeloma. Asia Pac J Clin Oncol 9(2):169–175 - PubMed
    1. Anaissie EJ, Coleman EA, Goodwin JA, Kennedy RL, Lockhart KD, Stewart CB et al (2012) Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer 118(2):549–557 - PubMed
    1. Anderson SM, Beck B, Sterud S, Lockhorst R, Ngorsuraches S (2019) Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma. J Oncol Pharm Pract 25(4):806–812 - PubMed
    1. Aurore, Palmaro Marie-Eve, Rougé-Bugat Martin, Gauthier Fabien, Despas Guillaume, Moulis Maryse, Lapeyre-Mestre (2017) Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database. Pharmacoepidemiology and Drug Safety 26(5) 578-586 10.1002/pds.4180 - PubMed
    1. Bellesoeur A, Thomas-Schoemann A, Allard M, Smadja D, Vidal M, Alexandre J et al (2018) Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences. Crit Rev Oncol Hematol 129:102–112 - PubMed

MeSH terms

LinkOut - more resources